- BMN-673 8R,9S
| VO-Ohpic trihydratePTEN inhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MS (Mass Spectrometry)
- MSDS (Material Safety Data Sheet)
- Elemental Analysis
- Datasheet
Chemical structure
| Kinase experiment [1]: | |
Phosphate release assay | For the detection of PTEN and Sac1 activities, bismuth was added to the phosphate release assay in order to improve its stability and sensitivity. All enzyme preparations were tested for linearity to ensure that suitable amounts of enzyme were employed in the inhibitor assays. Enzymes were incubated with VO-Ohpic Trihydrate at various concentrations prior to starting the phosphatase reaction by adding the corresponding substrates presented in octylglucoside mixed micelles. |
| Cell experiment [1]: | |
Cell lines | NIH 3T3 and L1 fibroblasts |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reaction Conditions | 0, 10, 20, 40, 75, 150 and 500 nM; 15 mins |
Applications | In NIH 3T3 and L1 fibroblasts, VO-Ohpic Trihydrate dose-dependently increased Akt phosphorylation at site Ser473 and Thr308. This effect reached saturation at 75 nM. |
| Animal experiment [2]: | |
Animal models | In-vivo ischemia and reperfusion mouse model |
Dosage form | 10 μg/kg; i.p. |
Applications | Inhibition of PTEN by VO-Ohpic Trihydrate decreased left ventricular systolic pressure and heart rate before ischemia, but resulted in an increase in cardiac functional recovery and a decrease in myocardial infarct size after ischemia-reperfusion. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Rosivatz E, Matthews J G, McDonald N Q, et al. A small-molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS chemical biology, 2006, 1(12): 780-790. [2]. Zu L, Shen Z, Wesley J, Cai ZP. PTEN inhibitors cause a negative inotropic and chronotropic effect in mice. Eur J Pharmacol. 2011 Jan 10;650(1):298-302. | |
VO-Ohpic trihydrate Dilution Calculator
calculate
VO-Ohpic trihydrate Molarity Calculator
calculate
| Cas No. | 476310-60-8 | SDF | Download SDF |
| Synonyms | VO-Ohpic;VO Ohpic | ||
| Chemical Name | N/A | ||
| Canonical SMILES | N/A | ||
| Formula | C12H16N2O11V | M.Wt | 415.2 |
| Solubility | ≥121.8 mg/mL in DMSO, ≥45.8 mg/mL in EtOH with ultrasonic, <2.25 mg/ml="" in="" h2o=""> | Storage | Store at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
VO-Ohpic is a highly selective small-molecule inhibitor of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) with IC50 value of 35 nM [1].Many research studies show that the lipid phosphatase activity of PTEN has certain cellular impacts, such as inhibition of proliferation, survival and regulation of insulin signaling. Meanwhile, the inhibition of PTEN’s lipid phosphatase activity increases glucose uptake triggered by the increase of PtdIns (3, 4, 5) P3. These suggest that small-molecule inhibitor of PTEN may have the potential of enhancing insulin sensitivity and overcoming insulin resistance, which would be beneficial for the development of diabetes therapeutics. VO-Ohpic is a specific vanadium-based inhibitor screened out from a range of synthesized vanadates and bpV complexes. [1]In vitro, VO-Ohpic inhibited the lipid phosphatase activity of recombinant PTEN with IC50 value of 35 nM. It was highly selective against PTEN over other recombinant phosphatases including CBPs, SopB, myotubularin, SAC1 and PTP-β. It inhibited CBPs and SopB with IC50 values in micromolar range and high nanomolar range, respectively. In NIH 3T3 and L1 fibroblasts, VO-Ohpic dose-dependently increased Akt phosphorylation at site Ser473 and Thr308. This effect reached saturation at 75 nM. VO-OHpic had no effect on insulin-stimulated tyrosine phosphorylation at concentrations up to 10 μM. Besides that, VO-Ohpic treatment was found to cause the functional activation of Akt, demonstrated by a corresponding reduction of the transcriptional activity of FoxO3a [1].In mice bearing MDA PCa-2b cell xenografts, administration of VO-Ohpic showed significant tumor growth suppression. Moreover, long term treatment of VO-Ohpic resulted in an increased survival of the treated animals. The tumors treated with VO-Ohpic displayed increased β-gal staining and decreased Ki-67 staining compared with the untreated control tumors [2].References:[1] Rosivatz E, Matthews J G, McDonald N Q, et al. A small-molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS chemical biology, 2006, 1(12): 780-790.[2] Alimonti A, Nardella C, Chen Z, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. The Journal of clinical investigation, 2010, 120(3): 681.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
培养一段时间后（一般小于一个细胞周期），固定细胞。根据所使用模拟核苷酸的不同，使用不同的方法。EdU，改变缓冲液的pH值，就会发出荧光。而BrdU则需用荧光抗体识别，需要对细胞膜和核膜进行通透处理。
再加入PI对DNA染色。
在二维坐标图上，横坐标设为线性PI荧光强度，纵坐标设为模拟核苷酸的荧光强度（log）。
典型的图就像下面一样：
G1, G2 和S期就按照图中的划分来做。G1期的细胞没有新合成DNA，所以BrdU信号是阴性，而PI的信号位于1倍体期。S期是正在合成DNA，所以BrdU都是阳性。G2期是已经合成好了2倍的DNA，所以位于2倍体期，信号是G1期的一倍。这个图中，G1 PI信号是300， G2就是600.
流式细胞仪（Flow cytometry ）是对细胞进行自动分析和分选的装置。它可以快速测量、存贮、显示悬浮在液体中的分散细胞的一系列重要的生物物理、生物化学方面的特征参量，并可以根据预选的参量范围把指定的细胞亚群从中分选出来。多数流式细胞计是一种零分辨率的仪器，它只能测量一个细胞的诸如总核酸量，总蛋白量等指标，而不能鉴别和测出某一特定部位的核酸或蛋白的多少。也就是说，它的细节 分辨率为零。
染色的各种染料，标记好的荧光抗体染色所需要的缓冲液，封闭液，PBS最终由于上样的缓冲液
不过还要考虑很多因素：标记的方法会不会影响细胞下面的培养细胞是否能够耐受长时间接触房间中的氧气和二氧化碳的浓度机器的无菌情况
（溶血）：红细胞，血红蛋白分解，红细胞溶解逃逸所述，称为溶血。通过各种物理和化学因素和毒素。在体外，如低渗溶液中，强烈的机械振荡，突然冷冻（-20℃-25℃）或突然化冻，过酸或过碱，以及乙醇，乙醚，皂碱，胆碱盐可引起溶血。人血浆的等渗溶液为0.9％NaCl溶液，红细胞在低于0.45％的NaCl溶液中，由于水的渗透，肿胀和红细胞破裂，血红蛋白逸出。在体内，溶血溶血性细菌侵入或某些毒素的抗原 - 抗体反应（如输入配血不合的血液），各种机械性损伤，红细胞内在（膜，酶）引起某些药物的缺陷。溶血性细菌，如某些溶血性链球菌和产气荚膜梭菌可导致败血症。的红血细胞和某些溶血性毒液含酶卵磷脂，卵磷脂血浆或红细胞成溶血卵磷脂，使红细胞膜分解疟原虫破坏。
比较常用的是用计数微球。比如临床上的CD4细胞绝对计数，就是采用这个方法。试管内事先已经有固定数目的计数微球和染色抗体。按要求加入固定体积的抗凝血液，裂解红细胞后上机。记录一千个微球，同时就会得到不同染色区域细胞的数量。这样就可以算出单位体积血液内CD4细胞的绝对数目了。
这样的计数微球也可以另外购买。浓度是固定的。在你已知体积的细胞悬液中加入一定体积的微球后上机，记录一千个微球的数据，细胞的计数也会同时记录。根据微球的浓度就可以推算出细胞的浓度，从而得出绝对计数了
另外一个方法是有些流式细胞仪是使用微泵加样，而不是连续吸取样本，这样样本的体积是已知的，记录一次就是所有样本的数量，可以算出细胞浓度
